School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
School of Science, China Pharmaceutical University, Nanjing 211198, China.
Molecules. 2023 Sep 16;28(18):6652. doi: 10.3390/molecules28186652.
With the advent of the aging society, osteoporosis (OP) risk increases yearly. Currently, the clinical usage of anti-OP drugs is challenged by recurrent side effects and poor patient compliance, regardless of oral, intravenous, or subcutaneous administration. Properly using a drug delivery system or formulation strategy can achieve targeted drug delivery to the bone, diminish side effects, improve bioavailability, and prolong the in vivo residence time, thus effectively curing osteoporosis. This review expounds on the pathogenesis of OP and the clinical medicaments used for OP intervention, proposes the design approach for anti-OP drug delivery, emphatically discusses emerging novel anti-OP drug delivery systems, and enumerates anti-OP preparations under clinical investigation. Our findings may contribute to engineering anti-OP drug delivery and OP-targeting therapy.
随着老龄化社会的到来,骨质疏松症(OP)的风险逐年增加。目前,无论口服、静脉或皮下给药,抗 OP 药物的临床应用都受到反复出现的副作用和患者顺应性差的挑战。通过适当使用药物传递系统或制剂策略,可以实现药物靶向递送到骨骼,减少副作用,提高生物利用度,并延长体内驻留时间,从而有效治疗骨质疏松症。本文阐述了 OP 的发病机制和用于 OP 干预的临床药物,提出了抗 OP 药物传递的设计方法,着重讨论了新兴的新型抗 OP 药物传递系统,并列举了正在临床研究中的抗 OP 制剂。我们的研究结果可能有助于工程抗 OP 药物传递和 OP 靶向治疗。